March 2025 Vol 16, No 3

It is important that all navigators fully understand biosimilars so that they can address the “nocebo” effect and help implement strategies to optimize their use, ensuring that patients receive cost-effective treatment without compromising quality of care.

An exciting new chapter begins for JONS as we welcome Harold P. Freeman, MD, to our Board as Editor Emeritus.

As biosimilars increase in the care arena of cancer treatment, it is critical that patients be informed of this classification of treatment in a way that allows for shared decision-making.

In this debut of a JONS regular feature focused on keeping oncology navigators at the forefront of their field, Mandi L. Pratt-Chapman, PhD, MA, HON-OPN-CG, explores recent revisions to the George Washington Cancer Center’s Oncology Patient Navigator Training program.

Researchers who evaluated the versatility and efficacy of the National Oncology Navigation Acuity Tool share their findings and suggest that the tool could become an essential asset in streamlining oncology care and maximizing the effectiveness of patient navigation services.

The significance of billing for navigation services remains a hot topic of discussion.

The Academy of Oncology Nurse & Patient Navigators (AONN+) is continuously working to listen to its membership, and one avenue is through a biennial membership survey. Here we present findings and insights from the 2024 AONN+ survey.